Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)

the TAS CC4 Study Group

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)'. Together they form a unique fingerprint.

Medicine & Life Sciences